Celgene (BUE:CELG) EPS (Basic): ARS375.98 (TTM As of Sep. 2019)


What is Celgene EPS (Basic)?

Celgene BUE:CELG 10 EPS (Basic) is ARS375.98 as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Celgene's basic earnings per share (Basic EPS) for the three months ended in Sep. 2019 was ARS133.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2019 was ARS375.98.

Celgene's EPS (Diluted) for the three months ended in Sep. 2019 was ARS129.75. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was ARS366.47.

Celgene's EPS without NRI for the three months ended in Sep. 2019 was ARS129.75. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2019 was 366.47.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Celgene's highest 3-Year average EPS without NRI Growth Rate was 109.70% per year. The lowest was 0.00% per year. And the median was 13.90% per year.

Celgene  (BUE:CELG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Celgene EPS (Basic) Related Terms

Celgene EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Celgene's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene EPS (Basic) Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.29 26.15 40.74 71.99 213.03

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.67 57.69 86.00 99.19 133.10

Celgene EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Celgene's Basic EPS for the fiscal year that ended in Dec. 2018 is calculated as

Basic EPS (A: Dec. 2018 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(152554.438-0)/716.300
=212.98

Celgene's Basic EPS for the quarter that ended in Sep. 2019 is calculated as

Basic EPS (Q: Sep. 2019 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(94570.865-0)/709.400
=133.31

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS375.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ARS375.98 mean?
Celgene (BUE:CELG) has a EPS (Basic) of ARS375.98 as of Sep. 2019. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Celgene and its competitors.
Is Celgene's EPS (Basic) too high?
Celgene's current EPS (Basic) is ARS375.98. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's EPS (Basic) compare to GILD and BIIB?
Celgene's EPS (Basic) of ARS375.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Celgene and its competitors. Celgene's current EPS (Basic) is ARS375.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current EPS (Basic) of ARS375.98. The current EPS (Basic) is ARS375.98. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Celgene (BUE:CELG), the current EPS (Basic) is ARS375.98 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.